Edwards Lifesciences Corp (EW)

Debt-to-capital ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	9,998,400	9,545,600	7,437,400	7,117,900	6,650,000	6,657,500	6,375,700	5,978,000	5,806,700	6,217,800	5,943,600	5,844,900	5,835,900	5,541,300	5,133,300	4,658,400	4,574,300	4,210,300	3,839,100	3,901,100
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

December 31, 2024 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $9,998,400K)
= 0.00

The debt-to-capital ratio for Edwards Lifesciences Corp has consistently remained at 0.00 from March 31, 2020, to December 31, 2024. This indicates that the company has not used debt in its capital structure during this period. A debt-to-capital ratio of 0.00 suggests that the company is relying on equity financing rather than debt to fund its operations and investments. This can be viewed positively by investors and creditors as it signifies a lower financial risk and less dependency on borrowed funds. However, it's essential to note that a zero debt-to-capital ratio could also point to missed opportunities for leveraging debt to potentially enhance returns or tax efficiency. Overall, maintaining a consistent zero debt-to-capital ratio may reflect Edwards Lifesciences Corp's conservative financial policy regarding debt management and its focus on maintaining a strong balance sheet position.